Pages that link to "Q42646408"
Jump to navigation
Jump to search
The following pages link to Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease (Q42646408):
Displaying 50 items.
- Brain imaging in Alzheimer disease (Q26996299) (← links)
- Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease (Q28287090) (← links)
- Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels (Q28488088) (← links)
- (-)-Phenserine attenuates soman-induced neuropathology (Q28539914) (← links)
- Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms (Q28552599) (← links)
- Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and [...] (Q28818062) (← links)
- Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. (Q30436083) (← links)
- Imaging endpoints for clinical trials in Alzheimer's disease (Q30885979) (← links)
- Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease (Q33520683) (← links)
- Multimodal techniques for diagnosis and prognosis of Alzheimer's disease (Q33607535) (← links)
- Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients (Q33715239) (← links)
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (Q34098866) (← links)
- Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies (Q34102715) (← links)
- Drug development for Alzheimer's disease: where are we now and where are we headed? (Q34166256) (← links)
- Why so few drugs for Alzheimer's disease? Are methods failing drugs? (Q34440659) (← links)
- Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease (Q34575780) (← links)
- The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders (Q34897526) (← links)
- Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls (Q35032948) (← links)
- A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis (Q35158547) (← links)
- Investigational drugs for the treatment of AD: what can we learn from negative trials? (Q35579234) (← links)
- Effective components of Chinese herbs reduce central nervous system function decline induced by iron overload (Q35746328) (← links)
- Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. (Q35840623) (← links)
- Age-associated learning and memory deficits in two mouse versions of the Stone T-maze (Q35875514) (← links)
- Anomalous PiB enhancement in the superior sagittal and transverse venous sinuses (Q35894684) (← links)
- Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (Q36005648) (← links)
- Fluid biomarkers in Alzheimer disease (Q36186513) (← links)
- Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment (Q36908486) (← links)
- Natural products as a source of Alzheimer's drug leads (Q37029561) (← links)
- Amyloid plaque imaging in vivo: current achievement and future prospects. (Q37054909) (← links)
- Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease (Q37122955) (← links)
- Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. (Q37163279) (← links)
- Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? (Q37198579) (← links)
- Molecular imaging as a guide for the treatment of central nervous system disorders (Q37262953) (← links)
- Phenserine Efficacy in Alzheimer's Disease (Q37510264) (← links)
- Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances? (Q37524877) (← links)
- Was phenserine a failure or were investigators mislead by methods? (Q37530878) (← links)
- Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease (Q37559812) (← links)
- The use of PET in Alzheimer disease (Q37688880) (← links)
- Biochemical markers in Alzheimer's disease clinical trials (Q37730012) (← links)
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (Q37769104) (← links)
- Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease (Q37814497) (← links)
- Stem cells for the treatment of neurodegenerative diseases. (Q37818596) (← links)
- Perfusion SPECT and FDG-PET. (Q37897692) (← links)
- CSF biomarkers for amyloid and tau pathology in Alzheimer's disease (Q37953330) (← links)
- Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic review (Q38076109) (← links)
- Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. (Q38127470) (← links)
- Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study (Q39613391) (← links)
- Progress in the development of new drugs in Alzheimer's disease (Q39789745) (← links)
- Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine (Q41467872) (← links)
- The perils of Alzheimer's drug development (Q42560979) (← links)